163 related articles for article (PubMed ID: 34330748)
1. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
2. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
[TBL] [Abstract][Full Text] [Related]
3. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
[TBL] [Abstract][Full Text] [Related]
4. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
Wang H; Del Mar N; Deng Y; Reiner A
Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
Front Mol Neurosci; 2022; 15():801757. PubMed ID: 35185467
[TBL] [Abstract][Full Text] [Related]
6. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
[TBL] [Abstract][Full Text] [Related]
7. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.
Reiner A; Wang HB; Del Mar N; Sakata K; Yoo W; Deng YP
Brain Res; 2012 Sep; 1473():161-72. PubMed ID: 22820300
[TBL] [Abstract][Full Text] [Related]
8. mGluR5 antagonism increases autophagy and prevents disease progression in the
Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
[TBL] [Abstract][Full Text] [Related]
9. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
11. Early defect of transforming growth factor β1 formation in Huntington's disease.
Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
[TBL] [Abstract][Full Text] [Related]
12. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
13. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
[TBL] [Abstract][Full Text] [Related]
14. Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.
Wang MJ; Li YC; Snyder MA; Wang H; Li F; Gao WJ
PLoS One; 2013; 8(4):e61787. PubMed ID: 23593498
[TBL] [Abstract][Full Text] [Related]
15. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
Woolley ML; Pemberton DJ; Bate S; Corti C; Jones DN
Psychopharmacology (Berl); 2008 Feb; 196(3):431-40. PubMed ID: 18057917
[TBL] [Abstract][Full Text] [Related]
16. mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.
Di Liberto V; Mudò G; Belluardo N
Neuropharmacology; 2011 Sep; 61(4):638-45. PubMed ID: 21619889
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Huntington's disease phenotype progression in male and female heterozygous FDNQ175 mice.
Li SH; Colson TL; Chen J; Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2023 Sep; 16(1):67. PubMed ID: 37726802
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with mGluR2 or mGluR3 Agonists Reduces Apoptosis Induced by Hypoxia-Ischemia in Neonatal Rat Brains.
Bratek-Gerej E; Bronisz A; Ziembowicz A; Salinska E
Oxid Med Cell Longev; 2021; 2021():8848015. PubMed ID: 33763176
[TBL] [Abstract][Full Text] [Related]
19. Environmental enrichment and a selective metabotropic glutamate receptor
Garcia EJ; Cain ME
Pharmacol Biochem Behav; 2020 May; 192():172907. PubMed ID: 32179027
[TBL] [Abstract][Full Text] [Related]
20. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease.
Yu D; Zarate N; White A; Coates D; Tsai W; Nanclares C; Cuccu F; Yue JS; Brown TG; Mansky RH; Jiang K; Kim H; Nichols-Meade T; Larson SN; Gundry K; Zhang Y; Tomas-Zapico C; Lucas JJ; Benneyworth M; Öz G; Cvetanovic M; Araque A; Gomez-Pastor R
Acta Neuropathol Commun; 2022 Jun; 10(1):83. PubMed ID: 35659303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
